Vor Biopharma Inc.

What they do

Vor Bio in-licensed telitacicept from RemeGen Co., Ltd. in June 2025, acquiring exclusive rights to develop and commercialize it outside Greater China; RemeGen retains Greater China rights. Telitacicept is a selective BAFF/APRIL inhibitor approved in China for gMG, SLE, RA, SjD and IgAN. Vor is running global Phase 3 trials in generalized myasthenia gravis and primary Sjogren's disease, and reports no revenue.

Revenue drivers

• Telitacicept (pre-revenue) — No product revenue has been generated since inception; the company states it does not expect revenue from product sales in the near future. Future revenue depends on approval and commercialization of telitacicept outside Greater China.
• Potential licensing/collaboration revenue — The 10-K says that if development succeeds or the company enters collaboration or license agreements, it may generate revenue from product sales or payments under such agreements. No such revenue has been recognized to date.

Recent performance

Net loss was $696.0 million for the year ended December 31, 2025, versus $116.9 million for 2024, with an accumulated deficit of $1,153.0 million at year-end 2025. The 2025 loss included $29.7 million of restructuring costs tied to the May 2025 wind-down of prior clinical and manufacturing operations and a 154-employee reduction (about 99% of the then-current workforce). For the three months ended June 30, 2026, net loss was $62.8 million, versus $1,573.7 million for the three months ended June 30, 2025; six-month losses were $282.4 million and $1,606.2 million, respectively. Operating cash flow was negative $142.7 million in 2025. Cash, cash equivalents and marketable securities were $466.1 million as of June 30, 2026.

Strategy

The company's stated priority is developing telitacicept in B cell-driven autoimmune disease, with a global Phase 3 in gMG (topline data anticipated in the first half of 2027) and a global Phase 3 in SjD that dosed its first patient in March 2026. It plans to enroll approximately 250 adults with SjD across the United States, Europe, South America and Asia in a randomized, double-blind, placebo-controlled trial. Vor assumed responsibility from RemeGen for the global gMG trial, which is recruiting in North America, Europe, Latin America and Asia. Management states cash, cash equivalents and marketable securities should fund operating expenses and capital expenditures into early 2029.

Risks

• No revenue and recurring losses — Vor has generated no revenue since inception and reported net losses of $696.0 million in 2025 and $62.8 million in the quarter ended June 30, 2026, with an accumulated deficit of $1,435.4 million at June 30, 2026.
• Cash sufficiency and funding needs — Management expects existing cash to fund operations into early 2029, but the company has continued to raise capital, including $48.9 million of gross ATM proceeds after June 30, 2026, and reported negative shareholder equity of $200.2 million at June 30, 2026.
• Reliance on in-licensed third-party asset — The entire pipeline depends on rights to telitacicept licensed from RemeGen in June 2025, with RemeGen retaining Greater China rights and continued involvement in development.
• Clinical and regulatory timing — gMG topline data are anticipated in the first half of 2027 and the SjD Phase 3 began dosing in March 2026, so approvals and any revenue remain subject to trial outcomes, enrollment and regulatory review.

Outlook

Management points to gMG global Phase 3 topline data anticipated in the first half of 2027 and a recently initiated global Phase 3 in SjD as the key catalysts. It states that cash, cash equivalents and marketable securities, plus expected 2026 private placement proceeds, should fund operations into early 2029. The company describes telitacicept as approved in China for gMG, SLE, RA, SjD and IgAN and as clinically validated in 8+ autoimmune indications in China.